Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy

Cancer Research

Volumn 59, Issue 11, 1999, Pages 2623-2628

  Heise, Carla C ^a   Williams, Angelica M ^a   Xue, Shirley ^a   Propst, Meisa ^a   Kirn, David H ^a  

^a ONYX PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS VECTOR;

ADENOVIRUS; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; FEMALE; GENE TARGETING; METASTASIS INHIBITION; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TISSUE DISTRIBUTION; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; CYTOPATHOGENIC EFFECT, VIRAL; DEFECTIVE VIRUSES; DNA, VIRAL; FEMALE; GENE THERAPY; GENETIC VECTORS; HT29 CELLS; HUMANS; IN SITU HYBRIDIZATION; INJECTIONS, INTRAVENOUS; LIVER NEOPLASMS; MICE; MICE, INBRED C57BL; MICE, NUDE; NEOPLASMS; TIME FACTORS; TRANSPLANTATION, HETEROLOGOUS; VIRUS REPLICATION;

EID: 0033152894     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Kozarsky, K. F., and Wilson, J. M. Gene therapy: adenovirus vectors. Curr. Opin. Genet. Dev., 3: 499-503, 1993.
2. Liu, T. J., Zhang, W. W., Taylor, D. L., Roth, J. A., Goepfert, H., and Clayman, G. L. Growth suppression of human head and neck cancer cells by the introduction of a wild-type p53 gene via a recombinant adenovirus. Cancer Res., 54: 3662-3667, 1994.
3. Clayman, G. L., el-Naggar, A. K., Roth, J. A., Zhang, W. W., Goepfert, H., Taylor, D. L., and Liu, T. J. In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma. Cancer Res., 55: 1-6, 1995.
4. Heise, C., Sampson, J. A., Williams, A., McCormick, F., Von, H. D., and Kim, D. H. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat. Med., 3: 639-645, 1997.
5. Bischoff, J. R., Kim, D. H., Williams, A., Heise, C., Horn, S., Muna, M., Ng, L., Nye, J. A., Sampson-Johannes, A., Fattaey, A., and McCormick, F. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science (Washington DC), 274: 373-376, 1996.
6. Rodriguez, R., Schuur, E. R., Lim, H. Y., Henderson, G. A., Simons, J. W., and Henderson, D. R. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res., 57: 2559-2563, 1997.
7. Sandig, V., Brand, K., Herwig, S., Lukas, J., Bartek, J., and Strauss, M. Adenovirally transferred p16INK4/CDKN2 and p53 genes cooperate to induce apoptotic tumor cell death. Nat. Med., 3: 313-319, 1997.
8. Arai, H., Gordon, D., Nabel, E. G., and Nabel, G. J. Gene transfer of Fas ligand induces tumor regression in vivo. Proc. Natl. Acad. Sci. USA, 94: 13862-13867, 1997.
9. Mujoo, K., Maneval, D., Anderson, S., and Gutterman, J. Adenoviral-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma. Oncogene, 12: 1617-1623, 1996.
10. Rosenfeld, M. E., Wang, M., Siegal, G. P., Alvarez, R. D., Mikheeva, G., Krasnykh, V., and Curiel, D. T. Adenoviral-mediated delivery of herpes simplex vims thymidine kinase results in tumor reduction and prolonged survival in a SCID mouse model of human ovarian carcinoma. J. Mol. Med., 74: 455-462, 1996.
11. Munshi, A., Ramesh, R., Marrogi, A., and Freeman, S. Evaluation of adenovirus p53-mediated "bystander effect" in vivo. Cancer Gene Ther., 4 (Suppl.): S13, 1997.
12. Nielsen, L. L., Gumani, M., Syed, J., Dell, J., Hartman, B., Cartwright, M., and Johnson, R. C. Recombinant El-deleted adenovirus-mediated gene therapy for cancer: efficacy studies with p53 tumor suppressor gene and liver histology in tumor xenograft models. Hum. Gene. Ther., 9: 681-694, 1998.
13. Kim, D., Ganley, I., Sampson-Johannes, A., Izbicka, E., Davidson, K., Von Hoff, D., and Heise, C. ONYX-015, a selectively replicating E1B-deleted adenovirus, has significant activity against human ovarian carcinoma alone and in combination with standard chemotherapeutic agents. Proc. Am. Soc. Clin. Oncol., 117: 211A, 1998.
14. Roth, J., and Cristiano, R. J. Gene therapy for cancer: what have we done and where are we going? J. Natl. Cancer Inst. (Bethesda), 89: 21-39, 1997.
15. Worgall, S., Wolff, G., Falck-Pedersen, E., and Crystal, R. G. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum. Gene Ther., 8: 37-44, 1997.
16. Duncan, S. J., Gordon, F. C., Gregory, D. W., McPhie, J. L., Postlethwaite, R., White, R., and Willcox, H. N. Infection of mouse liver by human adenovirus type 5. J. Gen. Virol., 40: 45-61, 1978.
17. Bao, J. J., Zhang, W. W., and Kuo, M. T. Adenoviral delivery of recombinant DNA into transgenic mice bearing hepatocellular carcinomas. Hum. Gene Ther., 7: 355-365, 1996.
18. Barker, D. D., and Berk, A. J. Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection. Virology, 156: 107-121, 1987.
19. Heise, C., Williams, A., Olesch, J., and Kim, D. H. Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: intratumoral spread and distribution effects. Cancer Gene Ther., in press, 1999.
20. Engelhardt, J. F., Ye, X., Doranz, B., and Wilson, J. M. Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc. Natl. Acad. Sci. USA, 91: 6196-6200, 1994.
21. Yang, Y., Li, Q., Ertl, H. C., and Wilson, J. M. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J. Virol., 69: 2004-2015, 1995.
22. Ginsberg, H. S., Moldawer, L. L., Sehgal, P. B., Redington, M., Kilian, P. L., Chanock, R. M., and Prince, G. A. A mouse model for investigating the molecular pathogenesis of adenovirus pneumonia. Proc. Natl. Acad. Sci. USA, 88: 1651-1655, 1991.
23. Prince, G. A., Porter, D. D., Jenson, A. B., Horswood, R. L., Chanock, R. M., and Ginsberg, H. S. Pathogenesis of adenovirus type 5 pneumonia in cotton rats (Sigmodon hispidus). J. Virol., 67: 101-111, 1993.
24. Straus, S. E. Adenovirus infections in humans. In: G. H. S. (ed.). The Adenoviruses, pp. 451-496. New York: Plenum Press, 1984.
25. Scaria, A., St. George, J. A., Gregory, R. J., Noelle, R. J., Wadsworth, S. C., Smith, A. E., and Kaplan, J. M. Antibody to CD40 ligand inhibits both humoral and cellular immune responses to adenoviral vectors and facilitates repeated administration to mouse airway. Gene Ther., 4: 611-617, 1997.
26. Guerette, B., Vilquin, J. T., Gingras, M., Gravel, C., Wood K. J., and Tremblay, J. P. Prevention of immune reactions triggered by first-generation adenoviral vectors by monoclonal antibodies and CTLA41g. Hum. Gene Ther., 7: 1455-1463, 1996.
27. Jooss, K., Turka, L. A., and Wilson, J. M. Blunting of immune responses to adenoviral vectors in mouse liver and lung with CTLA41g. Gene Ther., 5; 309-319, 1998.
28. Kim, D., Ganley, I., Nemunaitis, J., Otto, R., Soutar, D., Kuhn, J., Heise, C., Propst, M., Maack, C., Eckhardt, G., Kaye, S., and Von Hoff, D. A Phase I clinical trial with ONYX-015 (a selectively replicating adenovirus) administered by intratumoral injection in patients with recurrent head and neck cancer. Cancer Gene Ther., 4 (Suppl.):, S13, 1997.
29. Bergsland, E., Mani, S., Kim, D., Fell, S., Heise, C., Maack, C., and Venook, A. Intratumoral injection of ONYX-015 for gastrointestinal tumors metastatic to the liver: a Phase I trial. Proc. Am. Soc. Clin. Oncol., 117: 211A, 1998.
30. Freytag, S. O., Rogulski, K. R., Paielli, D. L., Gilbert, J. D., and Kim, J. H. A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy. Hum. Gene Ther., 9: 1323-1333, 1998.
31. Pawelek, J., Low, K., and Bermudes, G. Tumor-targeted Salmonella as a novel anti-cancer vector. Proc. Am. Assoc. Cancer Res., 4: 343, 1997.
32. Mineta, T., Rabkin, S. D., Yazaki, T., Hunter, W. D., and Martuza, R. L. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat. Med., 1: 938-943, 1995.
33. Chambers, R., Gillespie, G. Y., Soroceanu, L., Andreansky, S., Chatterjee, S., Chou, J., Roizman, B., and Whitley, R. J. Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma. Proc. Natl. Acad. Sci. USA, 92: 1411-1415, 1995.
34. Kim, D. H. Replicating oncolytic viruses: an overview. Expert Opin. Invest. Drugs. 5: 753-762, 1996.
35. Yuan, F., Dellian, M., Fukumura, D., Leunig, M., Berk, D. A., Torchilin, V. P., and Jain, R. K. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res., 55: 3752-3756, 1995.